Right Drug Dose Now Act of 2025
The Right Drug Dose Now Act of 2025 would direct the Department of Health and Human Services to update the National Action Plan for Adverse Drug Event Prevention to reflect current pharmacogenomic science. It requires HHS to report to Congress on implementation of the existing plan, reconvene the federal interagency steering committee on adverse drug events, and ensure the updated plan considers drug-gene and multi-drug interactions, the role of pharmacogenetic testing with clinical decision support, and ways to improve federal monitoring systems so they can better identify genetic links to adverse events.
The bill also focuses on education and health information technology. HHS would be directed to issue guidance for clinicians, health system leaders, educators, and genetics professionals on when pharmacogenomic testing may help prevent adverse drug reactions, how to use drug interaction alerts, when to consult genetics specialists, and how to report pharmacogenomic information to FDA’s adverse event system. In addition, the bill calls for guidance and updates to electronic health record and e-prescribing systems so they can flag when testing is appropriate, surface drug-gene and drug-drug-gene associations, and support direct reporting of adverse events to FDA, including patient-friendly reporting options such as mobile tools.
If enacted, the bill would not create a new insurance benefit or mandate testing for all patients, but it would change federal policy and guidance around pharmacogenomics, adverse drug event surveillance, and electronic health record functionality. It would require HHS, FDA-related systems, and the Government Accountability Office to produce reports, recommendations, and updated guidance, and it would push federal health IT standards toward better capture and use of genetic information in medication decision-making. The bill would affect federal agencies, health care providers, EHR vendors, and reporting systems used for drug safety monitoring, while indirectly influencing how clinicians incorporate genetic test results into prescribing and medication management.
The available context suggests generally favorable or bipartisan interest in the bill’s goals, as reflected by its introduction by Representatives Swalwell and Crenshaw, who are from different parties. The bill’s framing emphasizes patient safety, reducing adverse drug events, and modernizing health technology, which are typically viewed positively in health policy discussions. No committee transcript or vote record is available here, so there is no evidence of formal opposition in the provided materials.
The main areas where disagreement could arise are implementation and scope rather than the underlying objective. Potential points of contention include the cost and burden of updating EHR systems, the reliability and clinical readiness of pharmacogenomic testing, how often guidance should be revised as science evolves, and whether federal agencies should require or merely encourage certain alerting and reporting features. Stakeholders such as health IT vendors, providers, and genetics specialists may differ on how prescriptive the standards should be, while privacy and workflow concerns could also arise around storing and surfacing genetic information in routine care.